BCD Bioscience, a Precision Prebiotic Fiber Company, Raises $12M In Series A Funding to Develop Lead Products

DAVIS, Calif.--(BUSINESS WIRE)--BCD Bioscience, a biotechnology company creating precision prebiotics from natural fibers, today announced that it has completed an oversubscribed Series A financing round of $12 million led by Acre Venture Partners. Existing investors, Seventure Partners and iSelect Fund, upped their commitments for the round and new investors, Collaborative Fund and Skyviews Life Science, have joined.

The financing will be used to obtain regulatory approvals for lead products, upscale production capabilities, expand the product pipeline, and to continue to build out the prediction and screening platform. CEO Steve Watkins said, “We are extremely pleased to have secured the financing needed to convert our promising lead prebiotics into high-value products and commercial opportunities. I am also delighted that our ability to deliver during our seed phase in creating our prebiotic library, screening platform, and pipeline gave such confidence to our investors.”

“We are thrilled to have partnered with Steve and the entire BCD team. Their unique platform and precision prebiotics will be critical in advancing public health, as well as contributing to reducing waste in our food systems. As this space continues to evolve, BCD will play a critical role, not only in functional foods and medical nutrition, but also in therapeutics,” said Gareth Asten, Managing Partner at Acre Venture Partners.

ABOUT BCD BIOSCIENCE

BCD Bioscience was founded in 2019 as a spin-out from UC Davis, to exploit the functional and health benefits of oligosaccharides obtained from natural sources, including food waste material. The company has proven that its breakthrough technology can produce precision prebiotics from most natural fiber sources and has validated its science platform for rapid screening of prebiotics for precise functional properties, including impact on live biotherapeutics, microbial composition and function, and active metabolites (postbiotics). The platform is also able to deliver deep insights into carbohydrate structure and utilization of prebiotics by bacteria. Commercial applications include foods, nutritionals and therapeutics.

Steven Watkins
BCD Bioscience, Inc.
(530) 601-9827 EXT 800
https://www.bcdbio.com/contact